This bill establishes new requirements for food additives to be deemed "generally recognized as safe" (GRAS) under FDA oversight. Manufacturers must now submit detailed safety data - including evidence showing no carcinogenicity, reproductive toxicity, or developmental toxicity - to the FDA for review, replacing the previous reliance on historical use. The FDA must publicly post submissions, allow 60 days for public comment, and issue written determinations within a set timeline. Additionally, the bill mandates the FDA to reassess the safety of at least 10 food substances every three years, prioritizing those under existing petitions or regulations. It directly affects food manufacturers and the FDA, creating a more rigorous, evidence-based process for food additive safety.
This bill requires the Department of Homeland Security (DHS) to keep all personal information from DACA applications confidential. It prohibits sharing this data with U.S. Immigration and Customs Enforcement (ICE), U.S. Customs and Border Protection (CBP), or state/local law enforcement for any purpose other than administering the DACA program. Limited exceptions allow sharing only to prevent fraud, address specific national security threats, or investigate felonies unrelated to immigration status. The law directly protects DACA applicants and recipients by preventing their personal details from being used against them by law enforcement.
This bill creates a public database of residential appraisal data to increase transparency in mortgage lending. It requires major mortgage agencies (Fannie Mae, Freddie Mac, FHA, USDA, VA) to share appraisal data with the Federal Housing Finance Agency, including property details, appraisal methods, and borrower demographics like race and ethnicity. The data will be made publicly available in searchable formats to help identify potential issues in how appraisals are conducted across different communities. It also establishes a process for borrowers to request a review of an appraisal they believe is inaccurate or reflects discrimination.
This bill creates the Office of Climate Change and Health Equity within the Department of Health and Human Services to coordinate federal efforts addressing climate change's health impacts, with special focus on environmental justice communities and medically underserved populations. It requires the development of a National Strategic Action Plan within one year of enactment, to be updated annually, that identifies climate-related health risks and outlines strategies to protect vulnerable communities. The bill also establishes a science advisory board of experts and authorizes $10 million annually for the Office through fiscal year 2031 to support activities including tracking climate health risks, developing preparedness plans, and reducing greenhouse gas emissions in the health sector.
This bill creates a new legal pathway for individuals injured by pesticides. It allows people harmed by pesticide use - whether to their person or property - to sue the company that registered the pesticide in federal court for monetary damages. The law specifies that recovered damages can include both compensatory and punitive amounts (at the court's discretion), but excludes attorney fees or court costs. Crucially, it clarifies that this federal right of action does not override existing state laws, meaning affected individuals can also pursue claims under state regulations. The bill directly impacts pesticide registrants (companies) and anyone suffering pesticide-related harm.
This bill creates a federal grant program to help schools recruit and retain paraprofessionals - school support staff like teaching assistants - who work directly with students but lack full teaching credentials. It allocates funds to states based on prior Title I education funding, requiring states to prioritize schools serving high numbers of low-income students or designated "high-need" schools. Funds can be used for mentoring programs, professional development, credentialing (like special education or English learner certificates), and wage increases or bonuses for paraprofessionals. The program mandates annual reporting on wage baselines, paraprofessional numbers, and how funds were used to address shortages.
This bill prohibits Medicare from paying for orthotics or prosthetics delivered directly to patients without in-person training from a qualified provider (a "drop shipment"), ensuring beneficiaries receive proper fitting and use instructions. It expands the list of healthcare providers who can prescribe these devices to include physical therapists, occupational therapists, orthotists, and prosthetists. The bill also specifically requires Medicare to cover replacements for custom-fitted orthotics and custom-fabricated orthotic devices, aligning with existing rules for prosthetic replacements. These changes aim to improve patient safety and access to properly fitted devices under Medicare.
HR 4516, the Saving Lives and Taxpayer Dollars Act, prohibits the U.S. government or its aid partners from destroying food, medicine, vaccines, or other foreign assistance commodities before they expire, requiring these items to be redirected to intended beneficiaries instead. The bill mandates that agencies like USAID, State, and Agriculture must make every effort to donate or sell expired aid items to those in need before disposal. It also requires annual reports to Congress detailing any expired, spoiled, or destroyed aid items, including reasons for not redirecting them and associated costs. This directly affects U.S. foreign aid agencies and their global partners, ensuring aid reaches people facing hunger, disease, or health crises rather than being wasted.
This bill requires Medicaid programs to cover specific treatments for individuals with breast or cervical cancer. It adds a new provision to Medicaid rules that explicitly includes these patients in mandatory coverage, ensuring states must provide necessary care. The bill also mandates that Medicaid cover breast reconstruction surgery following a medically necessary mastectomy. These changes directly affect Medicaid beneficiaries diagnosed with breast or cervical cancer who need these specific treatments. The policy update removes gaps in existing coverage for these critical cancer care services.
HR 4545, the Medicare Breast Reconstruction Access and Information Act, requires healthcare providers to inform Medicare patients about coverage for breast reconstruction surgery before performing a mastectomy. The bill amends the Social Security Act to mandate that suppliers providing a mastectomy must explain that reconstruction is covered under Medicare's national coverage determination 140.2 and document this discussion in the patient's medical record. This applies specifically to Medicare beneficiaries undergoing medically necessary mastectomies. The law ensures patients receive clear information about existing coverage options prior to surgery, without changing Medicare's benefit structure.
This bill requires all federal agencies to set specific equity goals in their strategic and performance plans, mandating at least one goal or 20% of total goals focused on improving services for underserved communities and individuals. It establishes an "Agency Equity Advisory Team" with 10+ agency roles (including civil rights, data, and human capital leaders) and creates an "Equity Subcommittee" to coordinate across agencies on equitable practices. The bill also updates data officer responsibilities to prioritize equitable data collection, use, and sharing, including collaboration with community groups and state/local governments. It directly affects all federal agencies and aims to reshape how government services are delivered to populations systematically excluded from economic, social, and civic opportunities.
This bill prohibits federal and state governments from restricting access to FDA-approved medicines. It guarantees individuals the right to obtain these medicines without coercion and allows healthcare providers (like doctors and pharmacists) to prescribe or refer for them. The law blocks governments from implementing rules that single out or hinder the sale, provision, or use of FDA-approved drugs, such as bans on specific medicines or barriers to patient access. It does not affect the FDA's drug approval process or existing health insurance coverage requirements.
